The Impact of Type 2 Diabetes Mellitus on Treatment Outcomes in Patients Operated for Stage III Rectal Adenocarcinoma

Résumé fourni par la source

Introduction: Colorectal cancer (CRC) ranks as the world's fourth most prevalent cancer and is the third leading cause of death globally. Stage III CRC indicates localized spread to nearby lymph nodes without metastasis to other body parts. While numerous studies have explored outcomes in CRC patients based on various predictive factors, a comprehensive literature review has identified a gap in research specifically investigating surgical outcomes for stage III rectal adenocarcinoma in individuals with type 2 diabetes mellitus (DM2).Aim: To explore the impact of DM2 on treatment outcomes in patients undergoing surgery for stage III rectal adenocarcinoma.Patients and methods: Our retrospective cohort study involved 95 patients who underwent elective radical anterior rectal resection with established mechanical colorectal anastomosis. Patients were categorized into two groups based on DM2 status.Results: Univariate regression analysis demonstrated that DM2 patients face a significantly higher risk of preoperatively elevated carcinoembryonic antigen levels and postoperative complications such as surgical site infection, urinary issues, and anastomotic leakage. Kaplan-Meier analysis indicated a shorter time to complication onset, particularly anastomotic leakage, and a diminished overall survival in DM2 patients.Conclusion: DM2 emerged as a significant prognostic factor influencing the treatment outcomes of patients undergoing surgery for stage III rectal adenocarcinoma.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.